20151223_TIME Ph2b Lancet Oncology 2015_CP FR
Catégorie : 2015
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
Stephane Leung-Theung-Long, et al PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article Publication
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial
John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation
Transgene et SillaJen annoncent la révision de leur accord et font le point sur le développement clinique de Pexa-Vec
20151112_TG+SillaJen joint VERSION FR
Transgene annonce la première administration à l’Homme de TG1050, son produit d’immunothérapie contre l’hépatite B chronique
20151103_TG1050_VERSION FINALE FR
Transgene publie ses résultats financiers trimestriels au 30 septembre 2015
20151021 PR VF Q3 2015 FINAL
Transgene annonce sa participation à la conférence d’investisseurs, Ladenburg Thalmann 2015 Healthcare Conference à New York
23092015 CP ladenburg conf_FR
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication
Rapport financier du premier semestre 2015 (rapport semestriel)
20150910-CP résultats semestriels 2015 version finale
